Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Various Advanced Cancer × daratumumab × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Multiple Myeloma 92 Recurrence 16 Neoplasms 10 Lymphoma, Non-Hodgkin 5 Leukemia, Myeloid, Acute 4 Neoplasms, Plasma Cell 3 Hematologic Neoplasms 3 Smoldering Multiple Myeloma 2 Plasmacytoma 2 Lymphoma, Large B-Cell, Diffuse 2 Carcinoma, Non-Small-Cell Lung 2 Various Advanced Cancer 1 Triple Negative Breast Neoplasms 1 Precursor Cell Lymphoblastic Leukemia-Lymphoma 1 Personal Satisfaction 1 Patient Satisfaction 1 Patient Preference 1 Pancreatic Neoplasms 1 Myelodysplastic Syndromes 1 Microsatellite Unstable Colorectal Cancer 1 Lymphoma, T-Cell, Peripheral 1 Lymphoma, Mantle-Cell 1 Lymphoma, Follicular 1 Lymphoma, B-Cell 1 Lymphoma 1 Immunoglobulin Light-chain Amyloidosis 1 Hodgkin Disease 1 Hematologic Diseases 1 Disease 1 Amyloidosis 1

Interventions

Nivolumab 5 Ipilimumab 3 relatlimab 1 daratumumab 1 Fluorouracil 1 Cisplatin 1 BMS-986115 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02488759 2023-11-13

CheckMate358

Bristol-Myers Squibb

Phase 1/2 Completed

578 enrolled 19 charts

Various Advanced Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡